Recorded Presentation: From mAb to bAb
Developing drugs requires navigating complex technical, practical, and strategic challenges quickly. Optimizing a drug’s activity and effectiveness and subsequently considering the IP landscape are crucially important balancing acts. Here, we demonstrate how evitria’s extensive expertise in antibody production can help you engineer, reformat, and produce your therapeutic, using a case study for the transformation of a mAb into a bsAb.

Request presentation record
Speaker

Desmond Schofield
evitria AG
Chief Business Officer
As Chief Business Officer, Desmond Schofield leads strategic initiatives focused on fostering growth and innovation. His responsibilities include crafting and implementing strategies to enhance customer service and satisfaction within a constantly evolving market.
Learn more
How to choose a bispecific antibody format